To investigate this hypothesis, CD4+ and CD8+ T cell populations were evaluated in the spleens of tumor bearing mice that received ALX148 alone or in combination with anti-PD-1, which activates adaptive T cell responses by inhibition of the PD-1 checkpoint [56]. This evidence concerns the gene CD4 and neoplasm.